Expansion of revenue from the new medical-related business through a capital and business alliance with Matsuya R&D
First written in FY2021-Q3. 1 of 2 entries say "Dropped", first in FY2026. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026DroppedAnnual report
「Matsuya R&D Co.,Ltd － 800,000 －」
In the status of holdings of investment securities, the company’s holding of shares in Matsuya R&D Co.,Ltd changed from 800,000 shares in the previous fiscal year to no holdings in the current fiscal year, and the capital relationship is no longer reported. - FY2021-Q3First statedAnnual report
「Based on a resolution of the Board of Directors dated 14 May 2021, we entered into a capital and business alliance agreement concerning a new business with Matsuya R&D Co.,Ltd (hereinafter, “Matsuya R&D”). We and Matsuya R&D have agreed to share our respective expertise in new businesses, principally medical-related businesses, and promote business collaboration in planning, research, development, design, production and sales of new products. We acquired 100,000 common shares of Matsuya R&D, representing 3.8%, from Goto Hidetaka (後藤秀隆), a major shareholder of Matsuya R&D.」
On 14 May 2021, the company entered into a capital and business alliance agreement concerning a new business with Matsuya R&D and began initiatives to use the parties’ respective expertise in planning, research, development, design, production and sales, principally in the medical-related business. It acquired 100,000 shares of Matsuya R&D, representing 3.8% of voting rights.